U3 Pharma AG
http://u3pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From U3 Pharma AG
New Daiichi Structure Strengthens Oncology Focus
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
Oncology Deal-Making The Daiichi Way
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
Daiichi Denies OTC Business Sale But Would It Make Sense?
Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?
Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
- Other Names / Subsidiaries
-
- Daiichi Sankyo Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice